Laiyi Chua

Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease

Stephen L. Lowe, Brian A. Willis, Anne Hawdon et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 2021 · 120 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies

Helle Linnebjerg, Eric Chen Quin Lam, Mary Seger et al. · Diabetes Care · 2015 · 95 citations

Medicine, Pharmacokinetics, Pharmacology +14

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Ivelina Gueorguieva, Brian A. Willis, Laiyi Chua et al. · Clinical Pharmacology & Therapeutics · 2023 · 76 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis

Kristian Reich, Kimberley Jackson, Susan Ball et al. · Journal of Investigative Dermatology · 2018 · 53 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14

Duration of action of two insulin glargine products, <scp>LY2963016</scp> insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus

Helle Linnebjerg, Eric Chen Quin Lam, Xin Zhang et al. · Diabetes Obesity and Metabolism · 2016 · 30 citations · Full text

Medicine, Endocrinology, Pharmacology +15